The FDA issued a final guidance Tuesday on labeling for drugs and biologics approved on the accelerated approval path. The guidance is intended to help sponsors develop the Indications and Usage section of labeling for products that were approved on the basis of a surrogate endpoint or a clinical endpoint other than survival or irreversible morbidity.